Epicypher, Inc.
Durham, NC
- UEI
- UWNWSADJYYZ3
- CAGE
- 6XLY4
- Primary NAICS
- 325411 Medicinal and Botanical Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 6 Davis Dr, Durham, NC 27709, USA
- Website
- epicypher.com
- Founded
- 2012
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $0 |
| FY2023 | $33,056 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Epitranscriptomic resource lab supplies award | National Institute of Environmental Health Sciences (NIH) | $33,056 |
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| University Of Houston System | R21AR082713 | $94,095 |
Similar vendors
About the company
Epicypher, Inc., headquartered in Durham, North Carolina, is a for-profit manufacturer and developer of epigenetic research tools and molecular diagnostics, operating as a prime recipient of federal research grants from the National Institutes of Health and related agencies. The company holds no federal contract prime positions but competes in full-and-open federal grant programs serving biomedical research missions across thirteen distinct NIH institutes and centers.
Epicypher's grant footprint centers on development of proprietary epigenomic profiling platforms, detection reagents, and nucleosome-based research tools for studying histone post-translational modifications, chromatin-associated proteins, and related epigenetic features relevant to aging, cancer, neurological disease, and inflammatory pathologies. Recent grant work spans designer nucleosome (DNUC) substrate platforms, CUT&RUN and CUT&TAG genomic mapping assays, and specialized detection reagents including recombinant "super-reader" proteins and immunotethering-based assays. Representative grants include a $1.062 million NCATS Project Grant (CFDA 93.350) awarded September 2026 to develop Small Molecule Mapper (SMMAP) for mapping drug-chromatin interactions in drug development; a $3.747976 million NIA Project Grant (CFDA 93.866) awarded September 2025 to develop AgingPTMTM, a platform for studying combinatorial histone modifications in aging and Alzheimer's disease; a $999,268 NIAID grant (CFDA 93.855) awarded August 2026 for DAF-SEQ, a long-read sequencing assay for chromatin accessibility in primary immune cells; and a $33,055.75 NIEHS purchase order awarded September 2023 for delivery of pAG-Tn5 and pAG-MNase enzymes used in epitranscriptomic research.
Customer concentration sits heavily with the National Institutes of Health, accounting for 79% of awards by count. The top five NIH institutes—the National Institute of General Medical Sciences (18 awards), the National Institute of Allergy and Infectious Diseases (10 awards), the National Human Genome Research Institute (8 awards), the National Institute of General Medical Sciences (7 awards), and the National Cancer Institute (7 awards)—dominate the active portfolio. Grant activity has remained relatively stable at eight awards annually in 2022 and 2023, declining to two to three awards per year in 2024–2026. Seven awards reach ultimate completion within the next twenty-four months, presenting recompete and continuation opportunity.
Epicypher acts as prime recipient on 98% of its awards and as a sub-recipient on a single grant sub-award from the University of Houston System (April 2025) to engineer histone and nucleosome panels for screening lupus sera in systemic lupus erythematosus research. The company partners with university collaborators on many grants, including researchers at Baylor College of Medicine, University of Washington, Fred Hutchinson Cancer Center, Weill Cornell, Colorado State University, and Johns Hopkins University. Most work is performed in Research Triangle Park, Durham, North Carolina.
Quick answers
Is Epicypher, Inc. registered in SAM.gov?
Yes. Epicypher, Inc.'s SAM.gov registration is active through June 10, 2027.
How much has Epicypher, Inc. received in federal contracts?
Federal contracts obligated $33,056 to Epicypher, Inc. in fiscal years 2023 through 2027.
What is Epicypher, Inc.'s most recent federal award?
Epicypher, Inc.'s most recent federal grant award is Genomic profiling of drug-chromatin interactions for accelerated drug development research (R44TR006068), from National Center for Advancing Translational Sciences (NIH), on September 1, 2026.
On GovTribe
See Epicypher, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors